Literature DB >> 20923629

Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.

Carolyn I Rodriguez, James Bender, Sue M Marcus, Michael Snape, Moira Rynn, Helen Blair Simpson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20923629      PMCID： PMC3923525          DOI： 10.4088/JCP.09l05805blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  21 in total

Review 1.  Toward a neurobiology of obsessive-compulsive disorder.

Authors:  A M Graybiel; S L Rauch
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

2.  Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity.

Authors:  Jessica Darman; Stephanie Backovic; Sonny Dike; Nicholas J Maragakis; Chitra Krishnan; Jeffrey D Rothstein; David N Irani; Douglas A Kerr
Journal:  J Neurosci       Date:  2004-08-25       Impact factor: 6.167

3.  Benefit-risk assessment of acne therapies.

Authors:  D C Seukeran; E A Eady; W J Cunliffe
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

4.  Adults with early-onset obsessive-compulsive disorder.

Authors:  M C Rosario-Campos; J F Leckman; M T Mercadante; R G Shavitt; H S Prado; P Sada; D Zamignani; E C Miguel
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

5.  Neuroprotection in Huntington's disease: a 2-year study on minocycline.

Authors:  Raphael M Bonelli; Anna K Hödl; Peter Hofmann; Hans-Peter Kapfhammer
Journal:  Int Clin Psychopharmacol       Date:  2004-11       Impact factor: 1.659

6.  Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset.

Authors:  R D Gibbons; D Hedeker; I Elkin; C Waternaux; H C Kraemer; J B Greenhouse; M T Shea; S D Imber; S M Sotsky; J T Watkins
Journal:  Arch Gen Psychiatry       Date:  1993-09

7.  An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death.

Authors:  Darryl C Baptiste; Andrew T E Hartwick; Christine A B Jollimore; William H Baldridge; Gail M Seigel; Melanie E M Kelly
Journal:  Mol Pharmacol       Date:  2004-08-10       Impact factor: 4.436

8.  A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.

Authors:  S Evelyn Stewart; Eric A Jenike; Dianne M Hezel; Denise Egan Stack; Nicholas H Dodman; Louis Shuster; Michael A Jenike
Journal:  J Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.153

9.  Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection.

Authors:  Susan C Fagan; David J Edwards; Cesar V Borlongan; Lin Xu; Ankur Arora; Giora Feuerstein; David C Hess
Journal:  Exp Neurol       Date:  2004-04       Impact factor: 5.330

10.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11
View more
  15 in total

Review 1.  Obsessive-Compulsive Disorder: Autoimmunity and Neuroinflammation.

Authors:  Mona Gerentes; Antoine Pelissolo; Krishnamoorthy Rajagopal; Ryad Tamouza; Nora Hamdani
Journal:  Curr Psychiatry Rep       Date:  2019-08-01       Impact factor: 5.285

Review 2.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

Review 3.  Minocycline: therapeutic potential in psychiatry.

Authors:  Olivia M Dean; João Data-Franco; Francesco Giorlando; Michael Berk
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

4.  Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Pamela Flood; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2011-04       Impact factor: 4.384

Review 5.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

6.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853

Review 7.  Neuroinflammation and psychiatric illness.

Authors:  Souhel Najjar; Daniel M Pearlman; Kenneth Alper; Amanda Najjar; Orrin Devinsky
Journal:  J Neuroinflammation       Date:  2013-04-01       Impact factor: 8.322

Review 8.  Searching for host immune-microbiome mechanisms in obsessive-compulsive disorder: A narrative literature review and future directions.

Authors:  Emily A Troyer; Jordan N Kohn; Gertrude Ecklu-Mensah; Gajender Aleti; David R Rosenberg; Suzi Hong
Journal:  Neurosci Biobehav Rev       Date:  2021-02-24       Impact factor: 9.052

Review 9.  Modulating Neuroinflammation to Treat Neuropsychiatric Disorders.

Authors:  Franziska A Radtke; Gareth Chapman; Jeremy Hall; Yasir A Syed
Journal:  Biomed Res Int       Date:  2017-10-18       Impact factor: 3.411

Review 10.  Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.

Authors:  Zoya Marinova; De-Maw Chuang; Naomi Fineberg
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.